1. Acknowledgement to Referees

   Acknowledgement to Referees 08 November 2017 Pages: 705 - 708

2. The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

   • Angel Qin
   • Shirish Gadgeel

   Review Article 31 August 2017 Pages: 709 - 718

   

3. Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

   • Aiko Nagayama
   • Leif W. Ellisen
   • Aditya Bardia

   Review Article 08 November 2017 Pages: 719 - 739

   

4. Targeting FGFR in Squamous Cell Carcinoma of the Lung

   • Neda Hashemi-Sadraei
   • Nasser Hanna

   Review Article 06 July 2017 Pages: 741 - 755

   

5. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors

   • Fabiola Amair-Pinedo
   • Ignacio Matos
   • Jaume Capdevila

   Review Article 15 November 2017 Pages: 757 - 774

   

6. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

   • Zev A. Wainberg
   • Maria Alsina
   • Josep Tabernero

   Original Research Article Open access 24 October 2017 Pages: 775 - 785

   

7. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer

   • Yu Sunakawa
   • Akihito Tsuji
   • Wataru Ichikawa

   Original Research Article 24 October 2017 Pages: 787 - 794

   

8. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

   • Giovan Giuseppe Di Costanzo
   • Andrea Casadei Gardini
   • Raffaella Tortora

   Original Research Article 03 August 2017 Pages: 795 - 803

   

9. Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database

   • Amandine Gouverneur
   • Pauline Claraz
   • Pernelle Noize

   Original Research Article 11 October 2017 Pages: 805 - 814

   

10. Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib

    • Anke E. M. van Erp
    • Melissa H. S. Hillebrandt-Roeffen
    • Yvonne M. H. Versleijen-Jonkers

    Original Research Article Open access 24 October 2017 Pages: 815 - 826

    

11. Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase

    • Xiaohui Chang
    • Lin Zhou
    • Yang Xiang

    Short Communication 08 August 2017 Pages: 827 - 832

    

12. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)

    • Jean-Bernard Auliac
    • Isabelle Monnet
    • Christos Chouaid

    Short Communication 31 July 2017 Pages: 833 - 838

    

13. Comment on: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”

    • Arnaud Uguen

    Letter to the Editor 28 October 2017 Pages: 839 - 840

14. Author’s Reply to Arnaud Uguen: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”

    • Jean-Bernard Auliac
    • Christos Chouaid

    Letter to the Editor 28 October 2017 Pages: 841 - 842